Peter Mullins
Pain Medicine · Vancouver, WANPI 1750879466
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,402 of the $3,990 with a category attached, or 60.2%. Abbott accounts for 67.1% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $2,742, 3.8 times the $725 reported in 2022.
Across 33 payments — averaging $120.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$622
- Medtronic$241
- Nalu Medical, Inc.$194
- Vertos Medical, Inc.$190
- Saluda Medical Americas, Inc.$66
What the payments were for
- Travel & lodging$2,40260%
- Food & beverage$1,58840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $2,677 |
| Boston Scientific | 9 | $622 |
| Medtronic | 6 | $241 |
| Nalu Medical, Inc. | 1 | $194 |
| Vertos Medical, Inc. | 2 | $190 |
| Saluda Medical Americas, Inc. | 1 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,990 in reported general payments places this provider in the 65th percentile of 124 pain medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nucynta ErTapentadol Hcl | 13 | $15,331 |
| OxycontinOxycodone Hcl | 17 | $10,818 |
| Buprenorphine | 47 | $9,989 |
| Xtampza ErOxycodone Myristate | 18 | $8,325 |
| Metaxalone | 13 | $5,701 |
| Pregabalin | 399 | $5,061 |
| Fentanyl | 19 | $4,344 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 218 | $4,215 |
| Morphine Sulfate ErMorphine Sulfate | 63 | $4,093 |
| Oxycodone Hcl | 177 | $2,547 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 82 | $2,185 |
| Gabapentin | 87 | $1,434 |
| Naproxen | 11 | $1,284 |
| Lidocaine | 20 | $1,238 |
| Tizanidine Hcl | 72 | $932 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Vancouver
- Sloane YuVancouver$42K
- Benjamin PlattVancouver$18K
- Guannan GeVancouver$2K
- Jennifer LeeKirkland$318K
- Steven StanosSeattle$206K
- Corrie AndersonSeattle$102K
- Gregory TermanSeattle$95K
- Caroline HarstroemEverett$74K
- Praveen MambalamEdmonds$32K
- Miroslav BackonjaSeattle$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.